Oncimmune Holdings plc announced the pre-publication of the first results from its collaboration with Cedars-Sinai Medical Center in Los Angeles, entitled: "Paradoxical Sex-Specific Patterns of Autoantibodies Response to SARS-CoV-2 Infection"1. The paper focuses on the characterisation of sex-specific prevalence and selectivity of autoantibody responses to the SARS-CoV-2 virus. Since the beginning of the COVID-19 pandemic, there has been an unprecedented number of initiatives from the life sciences industry and research institutions to understand and respond to the effects of COVID-19, but despite first generation vaccines now being deployed to fight the disease, the need to expand understanding of the immune response to SARS-CoV-2 still exists. The results of this study demonstrate the potential of the SeroTagTM Infectious Diseases discovery array to enable a better understanding of how SARS-CoV-2 stimulates the immune reaction and predicts responses to vaccines and therapeutics against the virus. The aim of this initial research project was to use the SeroTag Infectious Diseases discovery array to detect autoantibodies to over 90 antigens previously linked to a range of classic autoimmune diseases. The researchers sought to comprehensively examine the diversity of autoantibody responses in male and female health care workers who were exposed to SARS-CoV-2 and were asymptomatic, or experienced minor symptoms.